ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p149.xmlThe Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p149.pdf2026-04-18The Emerging Role of Novel Therapies for the Treatment of Relapsed Myelomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p170.xmlMultiple Myeloma: Most Common End-Organ Damage and Management2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p170.pdf2026-04-18Multiple Myeloma: Most Common End-Organ Damage and Managementhttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p163.xmlRole of Bone Marrow Transplantation in the Disease Pathway of Myeloma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p163.pdf2026-04-18Role of Bone Marrow Transplantation in the Disease Pathway of Myelomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p117.xmlMyeloid Growth Factor Guidelines: Moving Toward a Societal Perspective2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p117.pdf2026-04-18Myeloid Growth Factor Guidelines: Moving Toward a Societal Perspectivehttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p118.xmlMultiple Myeloma Guidelines2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p179.xmlManaging Systemic Light-Chain Amyloidosis2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p179.pdf2026-04-18Managing Systemic Light-Chain Amyloidosishttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p188.xmlMyeloid Growth Factors Guidelines2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p203.xmlGrowth Factors in Leukemia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p203.pdf2026-04-18Growth Factors in Leukemiahttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p217.xmlSummary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p217.pdf2026-04-18Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p235.xmlAntibacterial Prophylaxis in Patients with Neutropenia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p235.pdf2026-04-18Antibacterial Prophylaxis in Patients with Neutropeniahttps://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p229.xmlMyeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/5/2/article-p229.pdf2026-04-18Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules